Masimo
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Masimo and other ETFs, options, and stocks.About MASI
Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge.
MASI Key Statistics
Stock Snapshot
With a market cap of 7.24B, Masimo(MASI) trades at $134.80. The stock has a price-to-earnings ratio of -12.24.
On 2026-01-14, Masimo(MASI) stock traded between a low of $128.89 and a high of $135.41. Shares are currently priced at $134.80, which is +4.6% above the low and -0.4% below the high.
Masimo(MASI) shares are trading with a volume of 185.04K, against a daily average of 626.59K.
In the last year, Masimo(MASI) shares hit a 52-week high of $194.88 and a 52-week low of $125.94.
In the last year, Masimo(MASI) shares hit a 52-week high of $194.88 and a 52-week low of $125.94.
MASI News
Masimo Corporation has already presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and released preliminary fourth-quarter and full-...
In a report released yesterday, Marie Thibault from BTIG maintained a Buy rating on Masimo, with a price target of $200.00. Claim 70% Off TipRanks Premium Unloc...
(RTTNews) - Masimo Corporation (MASI) on Monday shared preliminary figures for the fourth quarter and full year ending January 3, 2026, showing solid growth in...
Analyst ratings
73%
of 11 ratingsMore MASI News
Claim 70% Off TipRanks Premium Masimo ( (MASI) ) just unveiled an announcement. On January 12, 2026, Masimo announced select preliminary financial results for...
With no single headline event driving attention today, Masimo (MASI) is on investors’ radars as a medical technology maker with mixed return figures, as well as...